Aldeyra Therapeutics (ALDX) – FDA
-
Aldeyra Therapeutics (ALDX) Lays Out Clinical Development Plan for Resubmission of NDA for Reproxalap in Dry Eye Disease
-
Aldeyra Therapeutics (ALDX) Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ALDX Stock Lookup